Retispec
AI-powered eye exam for early detection of neurodegenerative diseases like Alzheimer's.
About
RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec's proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer's disease. RetiSpec is involved in multiple Alzheimer's and brain health studies in leading hospitals and research networks throughout North America.
Key facts
- Website
- retispec.com
- Headquarters
- Oulu, Finland
- Founded
- 2016
- Employees
- 33
- Total funding
- $11M (Series A)
- Valuation
- Private
- Business model
- B2B
- Tags
- HealthTechMedTechAI-Driven Drug DiscoveryClinical TrialsBiotech
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 26 Jul 2024 | Series A | $10M | iGan Partners |
| 1 Jun 2018 | Seed | $1M | - |
| 30 Jun 2017 | Pre-Seed | $100K | - |
Tech stack
Detected on retispec.com, last scanned 6 Sept 2026. Run your own scan
- Observability
- Sentry
- CMS / Builders
- Wix
- Email provider
- Google Workspace
Frequently asked
What does Retispec do?
RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer's disease and other causes of cognitive decline. RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimer's Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.
How much funding has Retispec raised?
Retispec has raised a total of $11M in funding. The most recent round on record is Series A.
How many employees does Retispec have?
Retispec has approximately 33 people on record.